Stock Catalyst AI
?? VIP Login VIP €10

Ticker archive · $ABBV

$ABBV Filing Signals & Market Reactions

Delayed, SEO-crawlable recaps of AI-scored catalysts for $ABBV — including observed post-filing price moves. Live streaming stays exclusive to VIP.

? All delayed signals

$ABBV

$ABBV – AbbVie Reports Q3 Adj. EPS Beat at $3.82, Raises Full-Year 2026 EPS Guidance

· TELEGRAM · All $ABBV
?? Positive AI Sentiment (+6.5 / 10)
  • Q3 Adj. EPS of $3.82 beats $3.74 consensus; Net Revenue of $17.40B beats $17.34B est.
  • Key drugs Skyrizi ($5.78B vs $5.74B) and Humira ($683M vs $679.3M) top estimates.
  • FY Adj. EPS guidance raised to $13.95-$13.99 from $13.76-$13.96 previously.
Observed market reaction after signal
Peak +0.63%
Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?
$ABBV

$ABBV – AbbVie beats Q3 estimates and raises full-year adjusted EPS guidance

· TELEGRAM · All $ABBV
?? Positive AI Sentiment (+6.5 / 10)
  • Q3 adj. EPS of $3.82 vs. $3.74 consensus; Net revenue of $17.40B vs. $17.34B est.
  • Key drugs beat: Skyrizi $5.78B vs. $5.74B, Rinvoq $2.71B vs. $2.70B.
  • FY adj. EPS guidance raised to $13.95-$13.99 from $13.76-$13.96.
Observed market reaction after signal
Peak +0.63%
Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?
$ABBV

$ABBV – AbbVie beats Q3 expectations across key franchises and raises FY EPS guidance

· TELEGRAM · All $ABBV
?? Positive AI Sentiment (+6.5 / 10)
  • Q3 Adj. EPS of $3.82 vs. $3.74 estimate; Net revenue was $17.40B vs. $17.34B expected.
  • Key drugs Skyrizi ($5.78B) and Rinvoq ($2.71B) beat consensus estimates.
  • Full-year adjusted EPS guidance raised to $13.95–$13.99 from prior $13.76–$13.96.
Observed market reaction after signal
Peak +2.17%
Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?
$ABBV

$ABBV – AbbVie Reports Q3 Net Revenue of $17.40B, Adjusted Diluted EPS of $3.82

AbbVie Inc.
· SEC_8K · All $ABBV
?? Positive AI Sentiment (+6.5 / 10)
  • Q3 Net revenues increased 10.3% reported (10.5% operational) to $17.404 billion.
  • GAAP diluted EPS reached $2.37; adjusted diluted EPS rose to $3.82 including a $0.11 IPR&D impact.
  • Humira erosion continues (-31.2%), offset by strong growth in core therapeutics portfolio.
Unlock Live VIP Terminal & Telegram – €10/mo Original filing ?